Last reviewed · How we verify
NCT06709586
Thermal Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism
trial testing Thermal ablation in Achievement Rate in 612 participants. Not yet recruiting.
26 November 2028
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 612 |
| Start date | 26 November 2024 |
| Primary completion | 26 November 2028 |
| Estimated completion | 30 December 2028 |
Drugs / interventions tested
- Thermal ablation
- parathyroidectomy
Conditions studied
- Achievement Rate — all drugs for Achievement Rate →
- Efficacy and Safety — all drugs for Efficacy and Safety →
- PTH — all drugs for PTH →
- Calcium — all drugs for Calcium →
Sponsor
Chinese PLA General Hospital
Who can join
18 and older, any sex, with Achievement Rate or Efficacy and Safety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Secondary hyperparathyroidism (SHPT), which is frequently associated with chronic kidney disease, leads to problems such as bone pain, fractures, and cardiovascular issues, thereby affecting patients' quality of life. This clinical trial is designed to compare the efficacy of thermal ablation and surgical treatment for SHPT. Parameters including parathyroid hormone levels, serum calcium and phosphorus levels, SHPT-related symptoms (for example, bone pain, muscle weakness), and complication occurrence will be monitored. The advantages involve enabling better treatment decisions for patients, enhancing patients' quality of life, and alleviating the burden on families, in addition to augmenting the clinical knowledge of healthcare providers. However, both treatments carry risks. Thermal ablation may have problems like incomplete ablation, local tissue damage, and blood parameter changes. Surgical risks comprise bleeding, infection, adjacent tissue damage (such as the recurrent laryngeal nerve), and hypoparathyroidism. The investigators will strive to minimize these risks. This trial is of great significance for SHPT treatment, and the investigators welcome participants to contribute to the advancement of medical science in this area.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06709586
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thermal ablation
Trials testing the same drug.
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
- NCT06708871 — Thermal Ablation Versus Parathyroidectomy for Primary Hyperparathyroidism · not yet recruiting
- NCT06609876 — Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC · NA · recruiting
- NCT05431699 — Single Visit Clinical Validation of ScreenFire, a Low-cost HPV Test · NA · active not recruiting
- NCT05129787 — Ablation vs Resection of Colorectal Cancer Liver Metastases · NA · active not recruiting
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06709586 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 29 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06709586.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing